Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
June 14 2021 - 7:05AM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced the appointment
of John E. Bishop, Ph.D., to the leadership team as senior vice
president and chief technology officer. In this role, Dr. Bishop
will lead chemistry, manufacturing and control (CMC)-related
functions and quality, encompassing Forma’s early pipeline through
commercial product.
“We are fortunate to welcome John to Forma at this pivotal time
in Forma’s history,” said Frank Lee, chief executive officer of
Forma. “John’s extensive expertise in small-molecule
pharmaceuticals and proven track record as a leader will help to
expedite drug development and commercialization at Forma, speeding
us on our mission of transforming the lives of patients with rare
hematologic diseases and cancers.”
Dr. Bishop’s background includes extensive expertise with CMC
development in oncology and hematology. Prior to joining Forma, Dr.
Bishop served as senior vice president of pharmaceutical sciences
at Epizyme, Inc., where he was a member of the executive team and
held overall responsibility for the CMC and quality assurance (QA)
functions. Prior to Epizyme, Dr. Bishop held positions of
increasing responsibility, including as senior vice president at
Momenta Pharmaceuticals, Inc. While at Momenta, Dr. Bishop planned
and oversaw expansion of the company’s CMC & QA functions from
an ad hoc, three-scientist operation to 130 full-time employees. He
also developed and executed successful CMC strategies for Momenta’s
generic versions of two complex drugs, enoxaparin sodium (LOVENOX®)
and glatiramer acetate (COPAXONE®), which led to Momenta’s
establishment of a broad biosimilar portfolio.
“I look forward to this opportunity to help Forma further
establish and scale a truly groundbreaking technical organization
that will enable the company to innovate in disease areas in urgent
need of new solutions,” said Dr. Bishop. “I believe the team at
Forma is applying world-class science and a sincere commitment to
patients, and I’m delighted to join this passionate group.”
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release may contain forward-looking statements and
information within the meaning of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. The use of
words such as “may,” “will,” “could,” “would,” “should,” “expects,”
“intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “projects,” “seeks,” “endeavors,” “potential,”
“continue,” “target” or the negative of such words or other similar
expressions can be used to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. The express or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation risks set forth under the caption
“Risk Factors” in Forma’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021, as well as other risks detailed in
our subsequent filings with the Securities and Exchange Commission.
In light of these risks, uncertainties and assumptions, the
forward-looking events and circumstances discussed in this press
release may not occur and actual results could differ materially
and adversely from those anticipated or implied in the
forward-looking statements. You should not rely upon
forward-looking statements as predictions of future events.
Although Forma believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee that
the future results, levels of activity, performance or events and
circumstances reflected in the forward-looking statements will be
achieved or occur. Moreover, except as required by law, neither
Forma nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release represents Forma’s views only as of the date on which it
was made. Forma undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005118/en/
Media Contact: Adam Silverstein, +1 917-697-9313 Porter
Novelli adam.silverstein@porternovelli.com
Investor Contact: Mario Corso, +1 781-366-5726 Forma
Therapeutics mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024